It is made available under a CC-BY 4.0 International license .

# 1 Title

2

- 3 Protocol for a Magnetic Resonance Imaging (MRI) Study of Participants in the Fever
- 4 Randomized Controlled Trial: Does fever control prevent brain injury in malaria?
- 5
- 6

## 7 Names of protocol contributors

8 Moses B. Chilombe<sup>1</sup>, Karl B. Seydel<sup>1,2</sup>, Colleen Hammond<sup>3</sup> Suzanna Mwanza<sup>4</sup>, Archana A. Patel<sup>5</sup>,

9 Frank Lungu<sup>6</sup>, Somwe wa Somwe<sup>6</sup>, Sam Kampondeni<sup>7,8</sup>, Michael J. Potchen<sup>8,9</sup>, Michael P.

10 McDermott<sup>10,11</sup>, Gretchen L. Birbeck<sup>6,11</sup>

11

12

## 13 Affiliations

- 14 1 Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi
- 15 2 Department of Osteopathic Medical Specialties, Michigan State University, East Lansing,
- 16 Michigan, USA
- 17 3 Department of Radiology, Michigan State University, East Lansing, Michigan, USA
- 18 4 Department of Pediatrics and Child Health, Chipata Central Hospital, Chipata, Zambia
- 19 5 Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA
- 20 6 University Teaching Hospitals Children's Hospital, Neurology Research Office, Lusaka,
- 21 Zambia
- 22 7 Mpingwe Clinic, Limbe, Malawi
- 23 8 Department of Imaging Sciences, University of Rochester, Rochester, New York, USA

Page 1 of 27

It is made available under a CC-BY 4.0 International license .

- 24 9 Zambia College of Medicine and Surgery, Lusaka, Zambia
- 25 10 Department of Biostatistics and Computational Biology, University of Rochester, Rochester,
- 26 New York, USA
- 27 11 Department of Neurology, University of Rochester, Rochester, New York, USA
- 28

## 29 **\*Corresponding Author**

- 30 Gretchen L. Birbeck
- 31 Email: gretchen\_birbeck@urmc.rochester.edu
- 32
- 33
- 34 **Protocol version**
- 35 Version 7.0 24June21
- 36

It is made available under a CC-BY 4.0 International license .

## 38 Abstract

39

## 40 Background

Despite eradication efforts, ~135,000 African children sustained brain injuries as a result of central nervous system (CNS) malaria in 2021. Newer antimalarial medications rapidly clear peripheral parasitemia and improve survival, but mortality remains high with no associated decline in post-malaria neurologic injury. A randomized controlled trial of aggressive antipyretic therapy with acetaminophen and ibuprofen (Fever RCT) for malarial fevers being conducted in Malawi and Zambia began enrollment in 2019. We propose to use neuroimaging in the context of the RCT to further evaluate neuroprotective effects of aggressive antipyretic therapy.

48

## 49 Methods

50 This observational magnetic resonance imaging (MRI) ancillary study will obtain neuroimaging 51 and neurodevelopmental and behavioral outcomes in children previously enrolled in the Fever 52 RCT at 1- and 12-months post discharge. Analysis will compare the odds of any brain injury 53 between the aggressive antipyretic therapy and usual care groups based upon MRI structural 54 abnormalities. For children unable to undergo imaging without deep sedation, 55 neurodevelopmental and behavioral outcomes will be used to identify brain injury.

56

## 57 **Discussion**

58 Neuroimaging is a well-established, valid proxy for neurological outcomes after brain injury in 59 pediatric CNS malaria. This MRI ancillary study will add value to the Fever RCT by determining if 60 treatment with aggressive antipyretic therapy is neuroprotective in CNS malaria. It may also help

It is made available under a CC-BY 4.0 International license .

- 61 elucidate the underlying mechanism(s) of neuroprotection and expand upon FEVER RCT safety
- 62 assessments.
- 63

### 64 Keywords

- 65 Seizures; neuro-disabilities; aggressive antipyretic therapy; neuroimaging; neurologic sequelae;
- 66 neuroprotection; CNS malaria; neurodevelopment; neurobehavior
- 67

It is made available under a CC-BY 4.0 International license .

Central nervous system (CNS) malaria, meaning *P. falciparum* parasitemia with neurologic

# 68 Introduction

### 69 Background

70

71 symptoms including impaired consciousness and/or seizures,<sup>1-4</sup> continues to be a major cause 72 of neuro-disabilities in African children. Brain injury with subsequent neurologic sequelae occurs 73 in one-third of children who survive CNS malaria. Newer antimalarial medications rapidly clear 74 peripheral parasitemia and improve survival, but mortality remains high with no documented 75 decline in post-malaria neurologic injury.<sup>5</sup> Common sequelae include epilepsy, gross motor 76 deficits, blindness, cognitive impairment, and behavioral disorders.<sup>1-4, 6-8</sup> 77 78 In the Blantyre Malaria Project Epilepsy Study (BMPES), a higher maximum temperature 79 (Tmax) during the acute infection was associated with a greater risk of post-malaria neurologic 80 sequelae. Children who developed epilepsy had a mean Tmax of 39.4°C vs. 38.5°C in those 81 who did not develop epilepsy (absolute difference of 0.9°C; p=0.01). In addition, those with 82 subsequent behavioral disorders had a higher Tmax than those who did not (39.2°C vs. 38.7°C; 83 absolute difference 0.5°C; p=0.04).<sup>1</sup> These data are consistent with the substantial body of 84 evidence that, within the peri-insult period, fevers contribute to secondary neurologic injury 85 across a wide range of conditions including stroke, meningitis, anoxia, hypoxia, and trauma.<sup>9-13</sup> 86 In the United States (US), induced hypothermia is now standard-of-care for post-anoxic<sup>14</sup> and 87 neonatal hypoxic-ischemic encephalopathy<sup>15-18</sup> and fever prevention is an important aspect of 88 neurocritical care.<sup>19-22</sup> In contrast to this aggressive and proactive approach to fever control, the 89 World Health Organization (WHO) malaria care guidelines recommend only modest measures 90 for fever control and these are to be used only in response to a significant febrile event.

It is made available under a CC-BY 4.0 International license .

91 Specifically, WHO malaria guidelines recommend treating a core temperature of  $\geq$  38.5°C with 92 acetaminophen 15 mg/kg (no loading dose) and explicitly recommend against the use of other 93 non-steroidal medications.<sup>23</sup> Malaria-induced fevers can be extremely high and there is no 94 evidence to date that a single antipyretic reduces malaria fevers. A controlled trial of 95 acetaminophen vs. placebo for uncomplicated malaria found no differences in mean 96 temperature, but 4% of children receiving placebo required admission for febrile seizures.<sup>24</sup> In 97 BMPES, WHO malaria care guidelines were followed and 15% of children experienced at least 98 one temperature of  $\geq$  40.0°C. The age-related susceptibility to pediatric malaria substantially 99 overlaps with the age-related phenomena of febrile seizures. Malarial seizures are often 100 complex, multifocal, and prolonged with status epilepticus being common.<sup>1, 7, 25, 26</sup> No malaria 101 studies to date have evaluated the impact of interventions using two antipyretics. 102 103 In 2019, a randomized controlled trial of aggressive antipyretic therapy for CNS malaria (Fever 104 RCT) launched in Malawi and Zambia.<sup>27</sup> This RCT compares prophylactic, scheduled 105 acetaminophen, including an initial loading dose of 30 mg/kg, plus ibuprofen for 72 hours after 106 presentation with CNS malaria to usual care based upon WHO guidelines over that same 107 period. The primary outcome of the RCT is Tmax. This observational MRI ancillary study will 108 determine whether the aggressive antipyretic therapy used in the Fever RCT resulted in fewer 109 brain injuries based upon neuroimaging or neurodevelopment and behavioral outcomes where

110 safe imaging is not possible.

111

### 112 Rationale

While a higher Tmax is associated with adverse neurologic outcomes in CNS malaria, causality
is not established. CNS malaria is a highly inflammatory process<sup>28, 29</sup> and inflammation-

It is made available under a CC-BY 4.0 International license .

115 mediated injury is a likely pathway for malaria-associated brain injury in this population, 116 particularly for epilepsy development. The aggressive antipyretic (AA) regimen used in the 117 Fever RCT may offer anti-inflammatory benefits in addition to fever-reduction. Neuroimaging of 118 the Fever RCT participants will facilitate identification of possible neuroprotective benefits from 119 AA treatment including anti-inflammatory benefits that might not be evident based upon acute 120 temperature measures. Previous research among cerebral malaria survivors in Blantyre has 121 shown that 53% suffer from cognitive and/or behavioral impairments at one year and these 122 impairments were associated with structural brain lesions on MRI including severe atrophy and 123 multifocal abnormalities.30 124 125 This study will also expand the safety assessments of the AA intervention. Ibuprofen may cause 126 bleeding due to its antiplatelet effects and is also nephrotoxic. Though frank CNS bleeds are not 127 associated with pediatric cerebral malaria.<sup>31</sup> end vessel micro-hemorrhages are seen post 128 mortem<sup>32, 33</sup> and have been identified on brain MRIs.<sup>34, 35</sup> MRI gradient recalled echo (GRE) 129 sequences available on standard MR equipment are sensitive to ferromagnetic substances and

130 will detect micro-hemorrhages. In Zambia where standard imaging is available, we will compare

131 the presence and characteristics of any CNS bleeding in the AA vs usual care (UC) groups.

132 Newly published data emerged after the Fever RCT commenced that shows a link between

133 cerebral malaria, acute kidney injury and the development chronic kidney disease (CKD),<sup>36</sup> so

134 the development of CKD after CNS malaria will also be compared using creatinine and the urine

albumin:creatinine ratio (ACR) assessed at least 6-months post-recovery.

136

## 137 Main Objectives

It is made available under a CC-BY 4.0 International license .

138 This prospective observational study will seek consent from parents of children previously

- 139 enrolled in the Fever RCT (Aggressive Antipyretics in CNS Malaria: A Randomized Controlled
- 140 Trial Assessing Antipyretic Efficacy and Parasite Clearance; National Institutes of Health Grant
- 141 R01NS102176; ClinicalTrials.gov NCT03399318) to obtain neuroimaging and
- neurodevelopmental & behavioral outcomes data on their child. The imaging and evaluations for
- 143 this observational study will occur after the child has recovered from the acute malaria infection
- and has otherwise completed the Fever RCT study. For some, consent will be sought months
- after the RCT-related activities for the child are completed. As such, this is an independent
- 146 observational study.
- 147

#### 148 **Specific Aims**

149 Aim 1:

150 To compare the prevalence of brain injury in the AA vs UC groups of the Fever RCT. Children

151 will undergo brain MRIs and neurodevelopmental & behavioral evaluations at 1 and 12 months

- after their acute malaria illness or as soon as possible among those children enrolled in the
- 153 Fever RCT prior to the initiation of this MRI ancillary study. Two radiologists, blinded to
- 154 treatment allocation, will independently review images and capture data using NeuroInterp.<sup>37</sup>
- 155 For children who are unable to undergo imaging without deep sedation, neurodevelopmental &
- behavioral evaluations will be used to identify those with brain injury.
- 157 We hypothesize that children who receive AA therapy during CNS malaria will have lower odds
- 158 of brain injury than those receiving UC.
- 159
- 160 Aim 2:

It is made available under a CC-BY 4.0 International license .

- 161 To compare the prevalence of specific structural injuries among children who received AA
- 162 therapy vs. UC therapy in the Fever RCT. Specifically, we will compare
- a. Overall atrophy by brain volume scoring<sup>38</sup> (atrophy being a brain volume score of 1-2 vs
- 164 ≥3)
- b. Gliosis by Fazekas score<sup>39</sup> (0, 1, 2 or 3)
- 166 c. The presence of regional gliosis or atrophy in the following regions
- 167 1. Cortical (present/absent)
- 168 2. Deep grey (present/absent)
- 1693. Corpus callosum (present/absent)
- 170 4. Posterior fossa (present/absent)
- 171
- 172 A priori pathophysiologic attributions are as follows:
- 173 -If focal cortical abnormalities are lower for the AA treatment group, we will conclude that the
- 174 mechanism(s) included seizure control/prevention
- 175 -If abnormalities are less common in the deep grey regions for the AA treatment group, we will
- 176 attribute this to benefits of reduced sequestration in the deep vascular beds
- 177 -If there is less diffuse atrophy or overall gliosis for the AA treatment group, we will attribute this
- 178 to reductions in increased intracranial pressure
- 179

180 Aim 3: Safety assessments

- a. In Zambia where standard imaging with GRE sequences is available, we will compare
- 182 the prevalence of blood products in the AA vs UC groups. If present, blood products will
- 183 be further characterized by age of blood relative to participation in the Fever RCT and
- 184 blood volume based upon number and size of foci.
- b. The prevalence of CKD based upon blood creatinine and urine ACRs will be compared

It is made available under a CC-BY 4.0 International license .

186 in the AA vs UC groups

187

# 188 Methods

- 189 All patient-contact will occur in Zambia and Malawi. All data transmitted or conveyed
- 190 beyond the country of enrollment will be de-identified.

191

## 192 Study sites

- University Teaching Hospitals-Children's Hospital, Lusaka,
- Chipata Central Hospital, Chipata, Zambia
- Queen Elizabeth Central Hospital, Blantyre, Malawi

196

- 197 Study sites without patient contact or access to data with private health information include:
- 198 University of Rochester, Rochester, NY, USA
- Michigan State University, East Lansing, MI, USA
- 200

## 201 Study design

- 202 Consented participants from the Fever RCT will undergo (1) a non-contrast brain MRI, (2)
- 203 neurodevelopmental & behavioral assessment, and (3) kidney function assessments with
- blood creatinine and urine ACR studies at 1 and 12 months post recovery, or as soon as
- 205 possible if their Fever RCT admission occurred prior to the launch of this observational study.

It is made available under a CC-BY 4.0 International license .

- 206 Based upon planned enrollment for the RCT (284), and considering anticipated mortality and
- 207 loss to follow-up, expected enrollment is 184 total.
- 208

## 209 Subject population

- 210 All children enrolled in the Fever RCT who survive to discharge are eligible for enrollment.
- 211 Inclusion and exclusion criteria for the Fever RCT are outlined below.
- 212

### 213 Eligibility criteria

#### 214 Inclusion Criteria for RCT

- Age 2-11 years (24 to 132 months)
- Evidence of *P. falciparum* malaria infection by peripheral blood smear or rapid diagnostic
   test
- CNS symptoms associated with malaria. This includes the most severe manifestation,
- 219 that being cerebral malaria (CM) with impaired consciousness via Blantyre Coma Score
- 220 (BCS) ≤2 in children under 5 years or a Glasgow Coma score (GCS) ≤10 in children ≥5
- 221 years; or less severe disease with complicated seizure(s), meaning prolonged (>15
- 222 minutes), focal or multiple; or other evidence of impaired consciousness (confusion,
- delirium) without frank coma (BCS>2, GCS=11-14)
- 224

#### 225 Exclusion Criteria for RCT

- Circulatory failure (cold extremities, capillary refill > 3 seconds, sunken eyes, decreased
   skin turgor)
- Vomiting in the past 2 hours

It is made available under a CC-BY 4.0 International license .

- Serum Cr > 1.2 mg/dL
- A history of liver disease
- Jaundice or a total bilirubin of >3.0mg/dL
- A history of gastric ulcers or gastrointestinal bleeding
- A history of thrombocytopenia or other primary hematologic disorder
- Petechiae or other clinical indications of bleeding abnormalities
- A known allergy to ibuprofen, acetaminophen, aspirin, or any non-steroidal medication
- Any contraindication for nasogastric tube placement and/or delivery of enteral

237 medications

238

### 239 **Recruitment Methods**

240 For children enrolled in the Fever RCT before this MRI ancillary study was commenced, consent 241 for future contact regarding possible research participation in subsequent relevant studies was 242 sought from the parents/guardians. This process was approved by the appropriate ethical and 243 institutional review boards. A list of those who consented by study identifiers (IDs) will be cross-244 referenced to the contact details including address and cell phone numbers maintained in the 245 study pharmacies. These parents/guardians will be contacted to seek consent for enrollment in 246 this observational study. If the parent/guardian is willing to consider enrollment, they will be 247 invited to come to the hospital for a full discussion and the consent process detailed below. 248 Children enrolled in the Fever RCT after this MRI ancillary study is launched will be identified as 249 potential participants when they have been stabilized and regained consciousness. Study 250 nurses working on the ward where the children are admitted will then approach the 251 parent/guardian for consent prior to discharge.

It is made available under a CC-BY 4.0 International license .

#### 252

#### 253 **Consent Process**

254 For children whose parents consented to be contacted regarding future studies, phone calls will

255 be placed and a brief overview of the study will be provided.

256

257 Consent and assent forms will be developed in English and the applicable local language.

258 Forward- and back- translation will be undertaken by expert local staff with extensive experience

in this regard. Staff obtaining consent are fluent in the local languages and expert in conducting

the informed consent discussion. All have Human Subjects Protection and Good Clinical

261 Practice certifications. The consent process will be conducted in the preferred language of the

262 parent/guardian. All parents/guardians who consent will be provided with signed copies of the

263 consent forms. For those parents/guardians who are unable to sign due to literacy limitations, a

thumb print will be obtained and someone who is not associated with the study but is literate in

the parent's/guardian's preferred language will be present during the consent process and will

sign as a witness. At the time of the return visit for evaluations, for children 7 years or older, if in

the parent's/guardian's assessment the child has the capacity to comprehend the nature of therequest, assent will also be sought.

269

#### 270 Study Procedures

271 Imaging

In Zambia, a 0.35T GE MRI will be used to obtain T1, T2 FRFSE, FLAIR, diffusion-weighted
imaging, GRE, GRE T2\*, proton density, STIR and 2-D and volumetric imaging. In Malawi, a
Hyperfine MRI adjacent to the research ward will be used and provides please insert. MRI
images will be reviewed by the technician at the time of the scanning and any findings of

It is made available under a CC-BY 4.0 International license .

- 276 concern that might warrant gadolinium administration will be reviewed by one of the study
- radiologists in real time to allow for gadolinium administration when the child is initially imaged.
- 278 However, if on review of an MRI about which the technical staff had no concerns the radiologist
- feels gadolinium is warranted for clinical care, the patient's family will be notified and all the
- same financial and logistical support will be provided for this repeat image. Two radiologists,
- 281 blinded to treatment allocation and neurologic status, will independently review images and
- 282 capture data using NeuroInterp. Disagreements will be reconciled first by consensus review and
- if reviewers still disagree, a third reader will make the final determination.
- 284
- 285 Neurodevelopmental & Behavioral
- At the 1- and 12-month evaluations, age-appropriate assessments will be undertaken by
- 287 dedicated local staff fully trained to deliver these measures. Data entry will be on tablets at the
- time of assessment. See Table 1 for details regarding instruments and criteria for a child to be
- categorized as brain injured.
- 290
- 291 Table 1: Neurodevelopmental & Behavioral Assessments and Ages for Testing

Instrument	Age	Criteria for Brain Injury
Malawi Developmental Assessment	3-5 years 11 months	≥ 2 standard deviations below
Tool (MDAT) <sup>40</sup>		the mean compared to age-
		specific Malawian norms
Neurological examination for subtle	7 years and above	Positive findings will be
signs (NESS) <sup>41</sup>		referred for clinical review
		and confirmation.

It is made available under a CC-BY 4.0 International license .

Behavioral Rating Inventory of		
Executive Function (BRIEF)42		
Preschool	2 years to 5 years 11 months	≥ 2 standard deviations below
School	6 years and up	the mean compared to
		previously established
		Western norms
Kaufman Assessment Battery for		
Children (KABC)43		
Preschool	6 years to 6 years 11 months	≥ 2 standard deviations below
School	7 years and up	the mean compared to age-
		specific Malawian norms
World Health Organization Epilepsy	All ages	Positive screen for epilepsy
Screening Questionnaire44		

292

293

294 *Kidney Function* 

295 Cr will be determined based upon analysis of whole blood captured via finger prick using a

296 STAT Sensor Creatinine Meter. Urine samples will be obtained for ACR measurements as well.

In Zambia, these will be obtained through a commercial lab. In Malawi, these will be assessed

with simultaneous measurement of urine albumin and creatinine on a Beckman Coulter AU480

299 machine with subsequent calculation of the ratio of the two analytes.

300

301 If any clinically relevant findings are identified, these will be discussed with the parent/guardian

302 and the appropriate referral for care will be made.

303

It is made available under a CC-BY 4.0 International license .

### **304 Dissemination**

305 Findings from this work will initially be presented at appropriate local venues before broader 306 dissemination. For example, University Teaching Hospital's Neurology Research-in-Progress 307 weekly meeting in Lusaka, Zambia; Zambia's Annual National Health Research Conference in 308 Lusaka, Zambia; the Wellcome Trust's Cutting-Edge weekly meeting, in Blantyre, Malawi and/or 309 Kamuzu University of Health Science's Research Dissemination Day in Blantyre, Malawi. With 310 approvals from Zambia's National Health Research Authority, findings will then be submitted to 311 peer reviewed journal(s) for publication and wider dissemination. Copies of published papers 312 will be submitted to the associated ethical review boards and the Zambian National Health 313 Research Authority.

314

#### 315 **Risks to Subjects**

Risks include loss of privacy, pain from finger prick, annoyance at the study assessments and
adverse effects from sedation. MRI-specific risks are largely associated with implanted devices,
which are not in use in the study populations of interest.

319

The study assessments including the neuroimaging are expected to take less than 2 hours. Regarding sedation risks--in our experience, Zambian and Malawian children as young as 6 years are able to tolerate clinical MRIs without sedation with a parent in the scanning room to comfort and encourage them. In Malawi, an existing sedation protocol utilizing chloral hydrate that has been in place for several years will be used. No serious adverse events have occurred in relation to chloral hydrate use in Malawi to date. An estimated 6% of Malawian children given chloral hydrate develop a paradoxical hypervigilance sometimes with irritability and agitation

It is made available under a CC-BY 4.0 International license .

327 lasting 4-6 hours. Nausea, vomiting and an allergic reaction are listed side effects of chloral 328 hydrate though these have not been seen during clinical use in children in Malawi over the last 329 decade. Children with a history of an allergy to or adverse reactions to chloral hydrate and those 330 with a history of a paradoxical response to other sedatives will not undergo sedation. Side 331 effects for chloral hydrate are dose related. Although standard protocol for clinical use of chloral 332 hydrate indicates repeated dosing if needed, no repeat dosing will be undertaken in this study. 333 Children who cannot cooperate sufficiently for MRI acquisition and for whom sedation is 334 deemed inappropriate or unsuccessful will not be imaged and their performance on the 335 neurodevelopmental and behavioral assessments will be used to identify brain injury. 336 337 In Zambia where chloral hydrate is not available, an alternative sedation strategy will be used--338 melatonin plus diphenhydramine. Melatonin is the standard sedative used for pediatric 339 electroencephalography in Zambia. Diphenhydramine in doses approved for over-the-counter 340 treatment of cold symptoms in children in Zambia will be added to the melatonin. Should a child 341 experience any adverse effects from sedation, a study clinician will evaluate them immediately. 342 Most anticipated side effects are self-limited and will resolve without intervention. If needed, the 343 clinician will provide analgesics for headache, anti-emetics for nausea, and oral rehydration 344 solution for vomiting. 345

#### **Potential Benefits to Subjects**

Children identified as having neurologic sequelae or kidney injury based upon the evaluations
will be referred for appropriate services that are available free of charge at both study sites.

#### **Cost of Participation**

It is made available under a CC-BY 4.0 International license .

351	Participants and their families will not be required to cover any of the costs associated with
352	participation. All study activities and procedures, as well as round trip transportation for the
353	children and their parents/guardians for these follow-up assessments, will be provided free-of-
354	charge.
355	
356	Payment for participation
357	In Malawi, for each study visit families will be reimbursed for the roundtrip travel costs
358	for the child and guardian. They will also receive remuneration consistent with
359	published guidelines, which is MWK4500.45
360	• In Lusaka, for each study visit families will be reimbursed for the roundtrip travel costs
361	for the child and guardian. They will also receive a total of ZMW260 for their time lost
362	from work, food during the testing day and their child's completion of the assessments
363	• In Chipata, for each study visit we will provide round trip transportation and overnight
364	accommodation for the child and a parent/guardian to travel to Lusaka. They will also
365	receive ZMW1060 for their time lost from work, food while traveling and the child's
366	completion of the assessments.
367	
368	Subject withdrawals

369 Parents/guardians may withdraw their children from the study at any time without impacting the

370 child's clinical care or any other adverse consequences.

371

### 372 **Privacy and Confidentiality of Subjects and Research Data**

373 To limit risk of loss of privacy, only the study ID number will identify all laboratory specimens,

374 evaluation forms, reports, and other records that leave the sites. All paper records will be kept in

It is made available under a CC-BY 4.0 International license .

375 secure study offices in locked filing cabinets. All computer entry and networking programs will 376 be done using study IDs only. Study data using only study IDs will be stored as follows: paper-377 based in the secure study offices at each site available only to study staff; neurodevelopmental 378 & behavioral outcomes and NeuroInterp data on the University of Rochester's Research 379 Electronic Data Capture (REDCap) and Malawi Malaria Alert Centre (MAC) server, and 380 neuroimaging files in DropBox with secured folders accessible only to study staff. Study staff will 381 ensure that imaging data and scanned paper-based forms with graphical or pictorial data 382 contain only the study ID and are saved in secured DropBox (i.e., non-public) folders. The study 383 offices are secured rooms with lockable file cabinets. All computers are password-protected. 384 DropBox folders containing de-identified data are non-public. 385 386 Clinical information will not be released without permission of the participant's parent or 387 guardian, except as necessary for monitoring by the appropriate institutional review boards 388 (IRBs), the US National Institute of Neurological Disorders and Stroke, the US Office for Human 389 Research Protections, the sponsor, or the sponsor's designee. If a family needs to be re-390 contacted for any reason (e.g., an imaging finding that is determined to warrant clinical follow-391 up), the study ID in this observational study will be cross-referenced against the contact details 392 for each child's family that are maintained as required in the study pharmacy for the RCT. 393 **Possible constraints** 394

This MRI ancillary study will commence after the Fever RCT is underway and as such we anticipate some loss to follow-up even among those who consent for future contact prior to discharge from the Fever RCT study.

398

It is made available under a CC-BY 4.0 International license .

#### 399 Data/Sample storage

- 400 De-identified imaging and neurodevelopmental & behavioral outcomes will be stored for future
- 401 use in secured DropBox folders and on the University of Rochester and Blantyre-based Malaria
- 402 Alert Centre servers.
- 403

# **Data and Safety Monitoring Plan**

This is an observational study. Potential adverse events include breach in confidentiality and any injuries or inconveniences related to participation in the clinical assessments and/or imaging acquisition. Any adverse events identified will be reported to the appropriate institutional review boards. Although not anticipated, should any Serious Adverse Events occur during the conduct of this observational study, the Local Study Monitors serving the RCT will be asked to review with their assessments provided to the overseeing IRBs.

411

### 412 Data Analysis Plan

413 The analysis of the presence of a brain injury (yes/no) will involve fitting a logistic regression 414 model with RCT treatment allocation group as the factor of interest, country as a stratification 415 factor, and a stratified propensity score<sup>46</sup> to account for the fact that the treatment groups will no 416 longer be the original randomized groups due to participants refusing consent and loss-to-417 follow-up. The propensity score will be estimated using a logistic regression model with 418 treatment group as the outcome variable and baseline covariate information that is thought to be 419 relevant to predicting adverse neurological outcome. These covariates include disease severity 420 (presence/absence of cerebral malaria), seizures prior to admission, admission temperature, 421 admission creatinine, sex, and age. The estimated treatment group odds ratio, along with its

It is made available under a CC-BY 4.0 International license .

422	associated 95% confidence interval and p-value, will be derived from this model. Similar
423	analyses will be conducted for the other outcomes of interest including the presence of the
424	specific imaging outcomes outlined in Aim 2, the presence of blood products; and the
425	prevalence of chronic kidney disease based upon an ACR of >1.2. For the ordinal gliosis
426	outcomes in Aim 2, a proportional odds logistic regression model will be employed; if the
427	proportional odds assumption appears to be seriously violated, a partial proportional odds
428	logistic regression model or a multinomial logistic regression model will be used instead.
429	
430	The sample size considerations are based on the logistic regression analyses to be performed
431	in Aim 1. Preliminary data indicate that 34% of pediatric CM survivors in Malawi have abnormal
432	brain MRIs at 1 month or a KABC falling at least 2 standard deviations below the population
433	norms for those over 7 years. <sup>43</sup> A sample size of 184 subjects (92 per group) will provide > 85%
434	power to detect a reduction in the percentage of subjects with structural injury from 35% in the
435	UC group to 15% in the AA therapy group, using a two-tailed test and a 5% significance level.
436	
437	Ethics approval and consent to participate.
438	Written informed consent will be obtained from all participant's parents or guardians.
439	
440	Study approval will be obtained from the following oversight entities prior to the conduct of this
441	work:
442	
443	The University of Zambia's Biomedical Research Ethics Committee FWA00000338
444	The University of Malawi's College of Medicine Research Ethics Committee
445	FWA00011868

It is made available under a CC-BY 4.0 International license .

446	The University of Rochester's Research Subjects Review Board (RSRB) FWA00009386
447	An intra-institutional reliance agreement will be generated between the University of
448	Rochester's RSRB and Michigan State University's Biomedical Institutional Review
449	Board FWA00004556
450	The National Health Research Authority in Zambia
451	
452	No human subjects contact will occur at any of the US-based sites. All data exported to the US
453	will be de-identified prior to transfer. All RSRB determinations regarding this work will be shared
454	with the non-affiliated researchers in a timely fashion.
455	

# 456 **Discussion**

- 457 When completed, this follow-up study of brain injury among children previously in the malaria
- 458 Fever RCT will determine whether AA treatment in the Fever RCT provided neuroprotection
- 459 benefits. This study may also help identify adverse events associated with AA treatment
- 460 including microhemorrhages and kidney injuring leading to CKD.

461

### 462 **Abbreviations**

- 463 BMPES Blantyre Malaria Project Epilepsy Study
- 464 CNS central nervous system
- 465 CM Cerebral Malaria
- 466 MRI Magnetic Resonance Imaging
- 467 MSU Michigan State University
- 468 RCT randomized controlled trial.

It is made available under a CC-BY 4.0 International license .

- 469 RSRB The University of Rochester's Research Subjects Review Board
- 470 Tmax maximum temperature PI Principal Investigator
- 471 UNZA BREC The University of Zambia's Biomedical Research Ethics Committee
- 472 UR- University of Rochester
- 473 UNZA BREC The University of Zambia's Biomedical Research Ethics Committee
- 474 UTH University Teaching Hospital

475

### 476 Authors' contributions

- 477 **Conceptualization:** Karl B. Seydel, Gretchen L. Birbeck, Michael Potchen
- 478 **Funding acquisition:** Gretchen Birbeck.
- 479 Imaging aspects: Sam Kampondeni, Michael Potchen, Colleen Hammond
- 480 **Investigation:** Gretchen Birbeck, Suzanna Mwanza, Karl B. Seydel
- 481 **Methodology:** Gretchen Birbeck, Karl B. Seydel, Michael P. McDermott
- 482 **Project administration:** Moses Chilombe, Gretchen L. Birbeck, Suzanna Mwanza
- 483 **Resources:** Gretchen L. Birbeck.
- 484 **Supervision:** Moses B. Chilombe, Karl B. Seydel, Suzanna Mwanza
- 485 Writing original draft: Karl B. Seydel, Gretchen L. Birbeck, Michael Potchen, Michael P.
- 486 McDermott
- 487 Writing review & editing: Moses B. Chilombe, Gretchen Birbeck, Karl B. Seydel, Michael P.
- 488 McDermott
- 489

### 490 **Funding**

491 Funded by the US National Institutes of Health (NIH) Grant R01NS111057.and R35NS122265

It is made available under a CC-BY 4.0 International license .

492 The investigators will have full access to the final dataset without any contractual limitations.

493

### 494 **Declarations**

- 495 Moses Chilombe has no disclosures.
- 496 Karl B. Seydel has received funding from the US NIH
- 497 Colleen Hammond has no disclosures.
- 498 Suzanna Mwanza has no disclosures
- 499 Archana A. Patel has received funding from the US NIH
- 500 Frank Lungu has no disclosures.
- 501 Somwe wa Somwe has no disclosures.
- 502 Sam Kampondeni has no disclosures.
- 503 Michael J. Potchen has received funding from the US NIH and is a paid medical legal
- 504 consultant.
- 505 Michael McDermott has received funding from the US NIH.
- 506 Gretchen L. Birbeck has received funding from the US NIH and is a paid consultant for
- 507 BlueSpark Technologies.
- 508

#### References

509

510 1. Birbeck GL, Molyneux ME, Kaplan PW, et al. Blantyre Malaria Project Epilepsy Study 511 (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: 512 a prospective cohort study. Lancet Neurol 2010;9:1173-1181.

513 2. Carter JA, Lees JA, Gona JK, et al. Severe falciparum malaria and acquired childhood 514 language disorder. Dev Med Child Neurol 2006;48:51-57.

515 3. Carter JA, Mung'ala-Odera V, Neville BG, et al. Persistent neurocognitive impairments 516 associated with severe falciparum malaria in Kenyan children. J Neurol Neurosurg Psychiatry 517 2005;76:476-481.

518 4. Carter JA, Neville BG, White S, et al. Increased prevalence of epilepsy associated with 519 severe falciparum malaria in children. Epilepsia 2004;45:978-981.

520 5. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment 521 of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. 522 Lancet 2010;376:1647-1657.

523 6. Carter JA, Ross AJ, Neville BG, et al. Developmental impairments following severe 524 falciparum malaria in children. Trop Med Int Health 2005;10:3-10.

525 7. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological 526 outcome of cerebral malaria. Lancet Neurol 2005;4:827-840.

527 8. John CC, Bangirana P, Byarugaba J, et al. Cerebral malaria in children is associated with 528 long-term cognitive impairment. Pediatrics 2008;122:e92-99.

529 9. WHO. Severe and complicated malaria. World Health Organization, Division of Control of 530 Tropical Diseases. Trans R Soc Trop Med Hyg 1990;84 Suppl 2:1-65.

531 10. Corbett D, Thornhill J. Temperature modulation (hypothermic and hyperthermic
 532 conditions) and its influence on histological and behavioral outcomes following cerebral ischemia.
 533 Brain Pathol 2000;10:145-152.

534 11. Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact of fever on outcome in
 535 patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke 2008;39:3029 536 3035.

Laptook AR, Corbett RJ. The effects of temperature on hypoxic-ischemic brain injury. Clin
 Perinatol 2002;29:623-649, vi.

539 13. Suz P, Vavilala MS, Souter M, Muangman S, Lam AM. Clinical features of fever associated
 540 with poor outcome in severe pediatric traumatic brain injury. J Neurosurg Anesthesiol 2006;18:5 541 10.

542 14. Arrich J, Holzer M, Herkner H, Mullner M. Cochrane corner: hypothermia for 543 neuroprotection in adults after cardiopulmonary resuscitation. Anesth Analg 2010;110:1239.

Lin ZL, Yu HM, Lin J, Chen SQ, Liang ZQ, Zhang ZY. Mild hypothermia via selective head
 cooling as neuroprotective therapy in term neonates with perinatal asphyxia: an experience from
 a single neonatal intensive care unit. J Perinatol 2006;26:180-184.

547 16. Low E, Boylan GB, Mathieson SR, et al. Cooling and seizure burden in term neonates: an 548 observational study. Arch Dis Child Fetal Neonatal Ed 2012;97:F267-272.

549 17. Schulzke SM, Rao S, Patole SK. A systematic review of cooling for neuroprotection in 550 neonates with hypoxic ischemic encephalopathy - are we there yet? BMC Pediatr 2007;7:30.

551 18. Smit E, Liu X, Jary S, Cowan F, Thoresen M. Cooling neonates who do not fulfil the 552 standard cooling criteria - short- and long-term outcomes. Acta Paediatr 2015;104:138-145.

553 19. Choi HA, Badjatia N, Mayer SA. Hypothermia for acute brain injury--mechanisms and 554 practical aspects. Nat Rev Neurol 2012;8:214-222.

555 20. Corry JJ. Use of hypothermia in the intensive care unit. World J Crit Care Med 2012;1:106-556 122.

557 21. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics 558 of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe 559 substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther 2008;84:52-62.

- 560 22. Scaravilli V, Tinchero G, Citerio G. Fever management in SAH. Neurocrit Care 561 2011;15:287-294.
- 562 23. WHO. WHO Guidelines for Malaria. 2022;425. Available at: WHO-UCN-GMP-2022.01-563 Rev.2-eng.pdf. Accessed 13Aug23.
- 564 24. Kofoed PE, Ursing J, Rodrigues A, Rombo L. Paracetamol versus placebo in treatment of 565 non-severe malaria in children in Guinea-Bissau: a randomized controlled trial. Malar J 566 2011;10:148.
- 567 25. Chomba E, Haworth A, Atadzhanov M, Mbewe E, Birbeck GL. The socioeconomic status 568 of children with epilepsy in Zambia: implications for long-term health and well-being. Epilepsy 569 Behav 2008;13:620-623.
- 570 26. Crawley J, Smith S, Kirkham F, Muthinji P, Waruiru C, Marsh K. Seizures and status 571 epilepticus in childhood cerebral malaria. QJM 1996;89:591-597.

572 27. Chilombe MB, McDermott MP, Seydel KB, Mathews M, Mwenechanya M, Birbeck GL. 573 Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-574 controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER 575 study). PLoS One 2022;17:e0268414.

- 576 28. Dammann O, Leviton A. Inflammation, brain damage and visual dysfunction in preterm 577 infants. Semin Fetal Neonatal Med 2006;11:363-368.
- 578 29. Moxon CA, Chisala NV, Wassmer SC, et al. Persistent endothelial activation and 579 inflammation after Plasmodium falciparum Infection in Malawian children. J Infect Dis 580 2014;209:610-615.
- 581 30. Langfitt JT, McDermott MP, Brim R, et al. Neurodevelopmental Impairments 1 Year After 582 Cerebral Malaria. Pediatrics 2019;143.
- S83 31. Potchen MJ, Kampondeni SD, Seydel KB, et al. Acute brain MRI findings in 120 Malawian
   children with cerebral malaria: new insights into an ancient disease. AJNR Am J Neuroradiol
   2012;33:1740-1746.
- 586 32. Pongponratn E, Riganti M, Punpoowong B, Aikawa M. Microvascular sequestration of 587 parasitized erythrocytes in human falciparum malaria: a pathological study. Am J Trop Med Hyg 588 1991;44:168-175.
- 589 33. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004;10:143-145.

Medhi N, Das SB, Das RR, et al. MRI findings of cerebral malaria. A report of two cases.
 Neuroradiol J 2009;22:407-412.

593 35. Rasalkar DD, Paunipagar BK, Sanghvi D, Sonawane BD, Loniker P. Magnetic resonance 594 imaging in cerebral malaria: a report of four cases. Br J Radiol 2011;84:380-385.

Solution and chronic kidney disease in a prospective cohort of children with severe malaria. BMC
 Med 2019;17:98.

598 37. Potchen MJ, Kampondeni SD, Ibrahim K, et al. NeuroInterp: a method for facilitating 599 neuroimaging research on cerebral malaria. Neurology 2013;81:585-588.

600 38. Kampondeni SD, Birbeck GL, Seydel KB, et al. Noninvasive measures of brain edema 601 predict outcome in pediatric cerebral malaria. Surg Neurol Int 2018;9:53.

Shu L, Zhong K, Chen N, et al. Predicting the severity of white matter lesions among
 patients with cerebrovascular risk factors based on retinal images and clinical laboratory data: a
 deep learning study. Front Neurol 2023;14:1168836.

605 40. Gladstone M, Lancaster GA, Umar E, et al. The Malawi Developmental Assessment Tool
606 (MDAT): the creation, validation, and reliability of a tool to assess child development in rural
607 African settings. PLoS Med 2010;7:e1000273.

608 41. Denckla MB. Revised Neurological Examination for Subtle Signs (1985). 609 Psychopharmacol Bull 1985;21:773-800.

42. Waschl N, Khng KH, Bull R, Ng EL, Sun H, Chan WT. Screening for executive function
difficulties: An evaluation of the Behavior Rating Inventory of Executive Function-2nd Edition
Screener, Teacher Report (BRIEF2-TS). Psychol Assess 2023;35:366-377.

43. Brim R, Mboma S, Semrud-Clikeman M, et al. Cognitive Outcomes and Psychiatric
Symptoms of Retinopathy-Positive Cerebral Malaria: Cohort Description and Baseline Results.
Am J Trop Med Hyg 2017;97:225-231.

44. Placencia M, Sander JW, Shorvon SD, Ellison RH, Cascante SM. Validation of a
screening questionnaire for the detection of epileptic seizures in epidemiological studies. Brain
1992;115 (Pt 3):783-794.

619 45. Gordon SB, Chinula L, Chilima B, et al. A Malawi guideline for research study participant
 620 remuneration. Wellcome Open Res 2018;3:141.

46. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a
treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.